Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer

Oncology

Volumn 74, Issue 1-2, 2008, Pages 76-83

  Matsubara, Junichi ^a   Yamada, Yasuhide ^a   Nakajima, Takako E ^a   Kato, Ken ^a   Hamaguchi, Tetsuya ^a   Shirao, Kuniaki ^a   Shimada, Yasuhiro ^a   Shimoda, Tadakazu ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Advanced gastric cancer; EGFR; Gastric cancer prognosticators; HER2; IGF 1R

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; IRINOTECAN; METHOTREXATE; PACLITAXEL; SOMATOMEDIN C RECEPTOR; UFT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 46249131607     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139127     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Furstenberger G, Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298-302.
3. Baserga R: Targeting the IGF-1 receptor: from rags to riches. Eur J Cancer 2004;40:2013-2015.
4. Brodt P, Samani A, Navab R: Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 2000;60:1101-1107.
5. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53:3736-3740.
6. Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 1990;50:6931-6935.
7. Adams TE, McKern NM, Ward CW: Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 2004;22:89-95.
8. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-269.
9. Takaoka M, Harada H, Andl CD, Oyama K, Naomoto Y, Dempsey KL, Klein-Szanto AJ, El-Deiry WS, Grimberg A, Nakagawa H: Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res 2004;64:7711-7723.
10. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
11. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001;37(suppl 4):S9-S15.
12. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A: Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer 1978;14:1291-1292.
13. Bonner RF, Emmert-Buck M, Cole K, Pohida T, Chuaqui R, Goldstein S, Liotta LA: Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481, 1483.
14. Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI, Danenberg PV: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-142.
15. Halpern J: Maximally selected chi square statistics for small samples. Biometrics 1982;38:1017-1023.
16. Lausen B, Schumacher M: Maximally selected rank statistics. Biometrics 1992;48:73-85.
17. Miller R, Siegmund D: Maximally selected chi square statistics. Biometrics 1982;38:1011-1016.
18. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59.
19. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) (abstract LBA4513). J Clin Oncol 2007;25(suppl):18S.
20. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
21. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL, Carbone DP: Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123:1191-1204.
22. Karp D, Paz-Ares L, Blakely L, Kreisman H, Eisenberg P, Cohen R, Garland L, Langer C, Melvin C, Gualberto A: Efficacy of the anti-insulin like growth factor I receptor (IGF-1R) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC) (abstract 7506). J Clin Oncol 2007;25(suppl):18S.
23. Higano C, Yu E, Whiting S, Gordon M, Lo-Russo P, Fox F, Katz T, Roecker J, Schwartz J: A phase I, first in man study of weekly IMCA12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors (abstract 3505). J Clin Oncol 2007;25(suppl):18S.
24. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
25. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664.
26. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18:510-517.
27. Iqbal S, Goldman B, Lenz H, Fenoglio-Preiser C, Blanke C: S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer (abstract 4621). J Clin Oncol 2007;25(suppl):18S.
28. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-207.
29. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O: Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006;119:2557-2566.
30. Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF, Corvaia N: A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005;113:316-328.
31. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R: Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-4299.
32. Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.